Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06987513 · ClinicalTrials.gov registry record · Phase 2
RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
A Phase 2 study of Alcohol Use Disorder (AUD), sponsored by Altimmune.
- Active
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 12
- Study locations
NCT06987513: Active Phase 2 study of Alcohol Use Disorder (AUD), sponsored by Altimmune.
NCT06987513 is a Phase 2 study of Alcohol Use Disorder (AUD) that is active but no longer recruiting, run by Altimmune. The registered enrollment target is 100 participants, below the 1,821-participant average among 30 other Alcohol Use Disorder (AUD) trials with a reported enrollment target (95% lower). The trial reports 12 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06987513, a Phase 2 study of Alcohol Use Disorder (AUD), is active but no longer recruiting, sponsored by Altimmune.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight. After signing the informed consent form, subjects will be screened and if eligible randomized 1:1 to 1 of the following 2 treatment arms: * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly
Primary Outcome
Change from baseline in the average number of heavy drinking days per week, with a heavy drinking day defined as 5 or more drinks in the day for men and 4 or more drinks in the day for women, using the Timeline Followback (TLFB) method
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Pemvidutide
Study Locations (12)
Florida
- Altimmune Clinical Study Site - Fort Myers
- Altimmune Clinical Study Site - University Park
Virginia
- Altimmune Clinical Study Site - Charlottesville
- Altimmune Clinical Study Site - Richmond
California
- Altimmune Clinical Study Site - Los Angeles
Colorado
- Altimmune Clinical Study Site - Aurora
Connecticut
- Altimmune Clinical Study Site - New Haven
Ohio
- Altimmune Clinical Study Site - North Canton
Oklahoma
- Altimmune Clinical Study Site - Tulsa
Pennsylvania
- Altimmune Clinical Study Site - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-05-15 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What the registry record for NCT06987513 still lists
NCT06987513 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,821-participant average among 30 other Alcohol Use Disorder (AUD) trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Alcohol Use Disorder (AUD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06987513 lists 12 locations in 10 states (Florida, Virginia, California).
Frequently Asked Questions
What is clinical trial NCT06987513 about?
NCT06987513 is a clinical study titled "RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight". This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight. After signing the informed consent form, subjects will be screened and if eligible randomized 1:1 to 1...
What is the current status of trial NCT06987513?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-05-15. Estimated completion is 2026-06.
What conditions does trial NCT06987513 study?
This clinical trial studies the following conditions: Alcohol Use Disorder (AUD).
What interventions are being tested in trial NCT06987513?
The interventions under investigation include: Placebo (OTHER), Pemvidutide (DRUG).
Who is sponsoring clinical trial NCT06987513?
This trial is sponsored by Altimmune, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06987513 being conducted?
This trial has 12 study locations across California, Colorado, Connecticut, Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder (AUD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06987513's enrollment target sits among peer trials
100 15th of 30 higher than 16 of 30 other Alcohol Use Disorder (AUD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder (AUD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
RECRUITING · Phase 2
-
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
RECRUITING · Phase 2
-
Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)
RECRUITING · Phase 2
-
Study of Tirzepatide for Recovery and Alcohol Use Management
RECRUITING · Phase 2
-
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
RECRUITING · Phase 2
-
Suvorexant for Treatment of AUD and PTSD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI